Related Experiment Video
Updated: May 5, 2026
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Elevated D-dimer levels after lecanemab infusions: a case report
Ming Zou1, Shan-Shan Xu1, Shi-Guo Zhu1
1Department of Neurology and Institute of Geriatric Neurology, the Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Background:
Lecanemab is a disease-modifying immunotherapy for Alzheimer's disease (AD) and has been increasingly prescribed to the patients in the world. It has a definite therapeutic effect in slowing cognitive decline in AD patients, but its adverse drug reactions should not be ignored.
Case Presentation:
We reported an 82-year-old Chinese AD patient who developed recurrent D-dimer elevation after lecanemab infusions. His D-dimer levels were positively correlated with activated partial thromboplastin time, C-reactive protein, and neutrophil percentage, but negatively correlated with platelet count.
Conclusions:
Elevated D-dimer levels may be associated with the enhanced phagocytic response to vascular amyloid β upon lecanemab treatment. Our report expands knowledge on lecanemab's adverse drug reactions, suggesting that D-dimer levels and potential thromboembolic events should be monitored during treatment.
Clinical Trial Number:
not applicable.
